Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The company granted stock options to purchase an aggregate of 97,400 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 66,750 shares of Nurix common stock.
One fourth of the total number of shares underlying the stock options will vest on the one-year anniversary of the employee's date of hire and one forty-eighth of the total number of shares underlying the stock options will vest each month thereafter until the stock option is fully vested on the fourth anniversary of the employee's date of hire, subject to the employee's continued service with Nurix on each such vesting date. The stock options have a term of ten years and an exercise price of $12.79 per share, which is equal to the closing price of Nurix's common stock on the grant date as reported by the Nasdaq Global Market.
One fourth of the total number of shares subject to the RSUs will vest on the one-year anniversary of the RSU vesting start date, which is July 30, 2025, subject to the employee's continued service with Nurix on the vesting date. Thereafter, one sixteenth of the total number of shares subject to the RSUs shall vest quarterly, until the RSU award is fully vested on the fourth anniversary of the vesting start date, subject to the employee's continued service with Nurix on each such vesting date.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix's partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix's dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine's next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit https://www.nurixtx.com.
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
23 minutes ago
- USA Today
US stock futures flat ahead of big box retailer results
U.S. stock futures are flat after a listless start to the week as investors stayed sidelined ahead of quarterly results from big box retailers and a conference of global financial leaders later this week. Discount giants Walmart and Target and home improvement company Lowe's are slated to report around midweek. Home Depot is due before the market opens. These earnings can provide a window into how tariffs are affecting companies and consumer spending. Federal Reserve Chair Jerome Powell is set to give a speech at the end of the week at the annual Jackson Hole Economic Symposium of global central bankers and finance chiefs. Investors will be looking for hints Powell may be done waiting to see tariff effects before cutting rates again. The CME FedWatch tool that shows the likelihood that the Fed will change rates at each policy meeting based on market trading suggests a nearly 84% chance of the Fed easing rates in September. Before Powell's speech, investors will get a glimpse midweek of the dissents at the last Fed meeting. Fed governors Christopher Waller and Michelle Bowman voted against the central bank's decision to keep rates unchanged between 4.25%-4.50% last month. It was the first time since 1993 that two governors dissented. At 6:10 a.m. ET, futures linked to the blue-chip Dow added 0.03%, while broad S&P 500 futures slipped -0.06% and tech-laden Nasdaq futures fell -0.05%. Corporate news Medora Lee is a money, markets and personal finance reporter at USA TODAY. You can reach her at mjlee@ and subscribe to our free Daily Money newsletter for personal finance tips and business news every Monday through Friday morning.
Business Wire
23 minutes ago
- Business Wire
GuidePoint Security Named to the Inc. 5000 List for the Tenth Consecutive Time
RESTON, Va.--(BUSINESS WIRE)-- GuidePoint Security, a cybersecurity solutions leader enabling organizations to make smarter decisions and minimize risk, today announced its inclusion on the Inc. 5000, Inc.'s annual list of the fastest-growing private companies in America. GuidePoint Security's growth is driven by an exceptional team of cybersecurity experts and an unwavering commitment to delivering top-tier tailored solutions. The list provides a data-driven snapshot of the most successful companies within the economy's most dynamic segment: its independent, entrepreneurial businesses. This year, GuidePoint Security ranks No. 2,470 and joins the Inc. 5000 10X Club, a rare feat that few organizations have achieved. 'We're honored to be named to the Inc. 5000 for the tenth consecutive year,' said Michael Volk, Chairman and CEO of GuidePoint Security. 'GuidePoint Security's growth is driven by an exceptional team of cybersecurity experts and an unwavering commitment to delivering top-tier tailored solutions. This recognition underscores our customer-first approach and marks an exciting milestone as we move into the next phase of our journey.' This year's Inc. 5000 honorees have demonstrated exceptional growth while navigating economic uncertainty, inflationary pressure and a fluctuating labor market. Among the top 500 companies on the list, the median three-year revenue growth rate reached 1,552 percent, and those companies have collectively added more than 48,678 jobs to the U.S. economy over the past three years. 'Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision,' says Mike Hofman, editor-in-chief of Inc. 'These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy.' This ranking follows a record-breaking first half for GuidePoint Security, fueled by strategic investments to fuel innovation and drive expansion. Over the past year, the company has surpassed 1,000 employees, opened three new offices—including a new global headquarters—and introduced new capabilities in cloud security, identity and access management, and AI/ML risk. GuidePoint has also expanded its 'as-a-service' portfolio with offerings such as Phishing-as-a-Service, while maintaining double-digit growth and industry-leading customer satisfaction and retention rates. For the full list, company profiles, and a searchable database by industry and location, visit: For more information on GuidePoint Security, please visit About GuidePoint Security GuidePoint Security provides trusted cybersecurity expertise, solutions, and services that help organizations make better decisions that minimize risk. Our experts act as your trusted advisor to understand your business and challenges, helping you through an evaluation of your cybersecurity posture and ecosystem to expose risks, optimize resources and implement best-fit solutions. GuidePoint's unmatched expertise has enabled 40% of Fortune 500 companies and more than half of the U.S. government cabinet-level agencies to improve their security posture and reduce risk. Learn more at More about Inc. and the Inc. 5000 Methodology Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2021 is $100,000; the minimum for 2024 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit
Business Wire
23 minutes ago
- Business Wire
Hercules Capital Receives a BBB+ Affirmed Investment Grade Corporate and Credit Rating from Kroll Bond Rating Agency, Inc.
SAN MATEO, Calif.--(BUSINESS WIRE)-- Hercules Capital, Inc. (NYSE: HTGC) ('Hercules' or the 'Company'), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Kroll Bond Rating Agency, Inc. ('KBRA') has affirmed Hercules' investment grade corporate and credit rating of BBB+. KBRA issued a statement announcing the affirmation of the rating and stable outlook, as well as its underlying analysis. The affirmed BBB+ rating reflects the Company's diversified investment portfolio with a focus on senior secured first lien venture debt investments in the technology and life sciences sectors, solid 20+ year operating record, including during the global financial crisis, and appropriate leverage metrics. The Company's solid credit quality has benefited from the Company's robust risk management and solid investment team with years of experience in the venture capital space. Furthermore, the ratings are supported by the Company's proven access to capital markets, diversified funding mix and high proportion of unsecured debt to total debt outstanding allowing for solid protection for noteholders. About Hercules Capital, Inc. Hercules Capital, Inc. (NYSE: HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology and life sciences industries. Since inception (December 2003), Hercules has committed more than $23 billion to over 690 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. Companies interested in learning more about financing opportunities should contact info@ or call 650.289.3060. Hercules, through its wholly owned subsidiary business, Hercules Adviser LLC (the 'Adviser Subsidiary'), also maintains an asset management business through which it manages investments for external parties ('Adviser Funds'). The Adviser Subsidiary is registered as an investment adviser under the Investment Advisers Act of 1940. Hercules' common stock trades on the New York Stock Exchange (NYSE) under the ticker symbol 'HTGC.' In addition, Hercules has one retail bond issuance of 6.25% Notes due 2033 (NYSE: HCXY). Forward-Looking Statements This press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. We may use words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'will,' 'should,' 'may' and similar expressions to identify forward-looking statements. Forward-looking statements are not guarantees of future performance and should not be relied upon in making any investment decision. Such statements are based on currently available operating, financial and competitive information and are subject to various risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations. While we cannot identify all such risks and uncertainties, we urge you to read the risks discussed in our Annual Report on Form 10-K and other materials that we publicly file with the Securities and Exchange Commission. Any forward-looking statements made in this press release are made only as of the date hereof. Hercules assumes no obligation to update any such statements in the future.
